FDA panel rejects Merck claim Zetia/Vytorin cut heart risk

Dec 14 (Reuters) - Merck & Co should not be allowed to claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease, an advisory committee to the U.S. Food and Drug Administration concluded on Monday. (Reporting by Toni Clarke in Washington; Editing by Eric Beech)